Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection.
Ontology highlight
ABSTRACT: Clostridioides difficile is the leading cause of health-care-associated infection throughout the developed world and contributes significantly to patient morbidity and mortality. Typically, antibiotics are used for the primary treatment of C. difficile infections (CDIs), but they are not universally effective for all ribotypes and can result in antibiotic resistance and recurrent infection, while also disrupting the microbiota. Novel targeted therapeutics are urgently needed to combat CDI. Bacteriophage-derived endolysins are required to disrupt the bacterial cell wall of their target bacteria and are possible alternatives to antibiotics. These lytic proteins could potentially replace or augment antibiotics in CDI treatment. We discuss candidate therapeutic lysins derived fro
SUBMITTER: Mondal SI
PROVIDER: S-EPMC7524323 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA